STXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Stereotaxis Inc (STXS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential with its revenue growth and upcoming product launch, the technical indicators are bearish, and the financials reveal ongoing losses and negative cash flow. Given the lack of clear trading signals and the current price trend, it is better to hold off on investing until more positive momentum or stability is observed.
The technical indicators for STXS are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 34.438, and the moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downtrend. The stock is trading near its key support level of 1.903, with resistance levels at 2.273 and 2.388.
Revenue growth of 36% YoY in Q4
Upcoming launch of MAGiC with Pulse Field Ablation in Europe by year-end.
Analyst rating of 'Outperform' with a $4 price target, citing unique MedTech potential.
Net income dropped by 25.39% YoY, and the company reported negative free cash flow of $13.8 million.
Operational costs of $10 million in Q4 impacted profitability.
Technical indicators are bearish, and the stock trend suggests a potential short-term decline.
In Q4 2025, revenue increased by 36.31% YoY to $8.64 million. However, net income dropped to -$5.85 million, and EPS declined to -$0.06. Gross margin slightly decreased to 50.07%, and the company reported negative free cash flow of $13.8 million.
Citizens initiated coverage with an 'Outperform' rating and a $4 price target, citing the company's innovative MedTech solutions and potential for system adoption and utilization growth through 2026.
